Thymogen: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 10 sources cited

Overview

Thymogen (Glu-Trp) is a synthetic dipeptide bioregulator designed to mimic the immunomodulatory activity of thymic peptides. Developed at the Russian Institute of Bioregulation and Gerontology, it is used clinically in Russia as an immunostimulant for treating immunodeficiency states, chronic infections, and as an adjunct in post-surgical recovery. It represents the simplest active thymic peptide fragment.

Mechanism of Action

Thymogen's dipeptide sequence (glutamic acid-tryptophan) is proposed to interact with immune cell receptors and gene regulatory elements to modulate T-cell maturation and function. It enhances the differentiation of T-cell progenitors in the thymus, increases the ratio of CD4+ helper T cells, and normalizes the CD4/CD8 ratio in immunocompromised states. Thymogen also modulates cytokine production — in laboratory studies it increased IL-2 and interferon release from blood lymphocytes; a selective effect on Th1 versus Th2 responses has not been shown. At the molecular level, the Glu-Trp dipeptide is thought to interact with transcription factors involved in T-cell gene expression, including those regulating TCR signaling components.

Thymogen Benefits: What the Research Shows

  • Russian clinical trials demonstrated improved immune parameters (CD4/CD8 ratio, total T-cell count) in patients with secondary immunodeficiency
  • Small Russian studies reported better clinical results when thymogen was added to treatment of chronic suppurative bronchitis and destructive pulmonary tuberculosis
  • A double-blind, placebo-controlled study in elderly patients having abdominal tumor surgery found that a week of intranasal thymogen before surgery restored cellular immunity measures and reduced post-operative complications (Advances in Gerontology, 2011)
  • Khavinson et al. documented thymogen's ability to normalize dysregulated immune function in elderly patients
  • In mice infected with influenza A, thymogen lowered the death rate without direct antiviral activity; it had no effect against influenza B (Zhurnal mikrobiologii, epidemiologii i immunobiologii, 1993)

Thymogen Dosage

  • Russian clinical protocol: 100 mcg intramuscularly or subcutaneously daily for 3–10 days
  • Intranasal form: 25 mcg per nostril, 1–2 times daily for 10 days
  • Oral supplementation: available as capsules at 10–25 mg daily for 10–30 days
  • Repeat courses every 1–3 months as needed for chronic immunodeficiency
  • Often used prophylactically during cold/flu season: 10-day courses monthly
  • Can be combined with other thymic peptides for comprehensive immune support
Peptide calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Thymogen Side Effects & Safety

Known Side Effects

  • Generally very well tolerated with minimal side effects
  • Rare: mild allergic reactions at the injection site
  • Transient low-grade fever (sign of immune activation) in some patients
  • No serious toxicity was reported in Russian clinical studies or in Western trials of the intranasal form (IM862), where side effects were limited to mild, transient headache, fatigue, tingling and nausea

Safety Profile

Thymogen has been approved and used clinically in Russia for over 20 years with an excellent safety record. In clinical trials it showed little toxicity; its immunogenicity has not been studied. It does not suppress immune function — it modulates and normalizes it, making it theoretically safer than broad immunosuppressants or stimulants. However, caution is advised in autoimmune conditions where T-cell stimulation could exacerbate disease. In the West the same dipeptide was tested as IM862 for cancer: it was well tolerated, but a 202-patient phase III trial in AIDS-related Kaposi's sarcoma found it no better than placebo, with a shorter time to progression in the treated group. Not recommended in patients with organ transplants on immunosuppressive therapy. Drug interactions have not been formally studied.

What to Expect

Day 1–3: No obvious effects. Immune modulation is occurring at the cellular level. Day 3–7: Subtle improvement in overall vitality. Patients with active infections may notice slightly faster resolution. Day 7–10: Course is typically completed. In small Russian studies of patients with immune disorders, T-cell counts and ratios improved after a course. Post-course: How long any effect lasts has not been established. Users often report fewer colds, faster recovery from illness, and improved general resistance to infection. Repeat courses extend and reinforce these effects.

Common Stacks

Storage & Handling

Store at 2–8°C for injectable form. Capsules can be stored at room temperature (15–25°C), protected from moisture. Shelf life: 2 years for capsules, 1 year for injectable solution. Intranasal spray: store at 2–8°C and use within 30 days of opening.

Pricing & Available Variants

$60price range
20mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Noy A, Scadden DT, Lee J, et al. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005.
  2. Tulpule A, Scadden DT, Espina BM, et al. Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 2000.
  3. Smirnov VS, Petlenko SV, El'tsin SS. Application thymogen for preoperative preparation of elderly patients with tumor processes in abdominal cavity. Adv Gerontol. 2011.
  4. Morozov VG, Khavinson VK. Natural and synthetic thymic peptides as therapeutics for immune dysfunction. Int J Immunopharmacol. 1997.
  5. Deigin V, Linkova N, Vinogradova J, et al. The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples. Int J Mol Sci. 2024.
  6. Litvinova NV, Eremeev VV, Abramova ZP, et al. Changes of immune and non-specific reactivity in patients with chronic suppurative obstructive bronchitis in comprehensive treatment with thymogen. Probl Tuberk. 1994.
  7. Medus AI, Pisarevskaia LI, Nikishina EV. The effect of thymogen on the state of immunity in destructive pulmonary tuberculosis. Voen Med Zh. 1999.
  8. Furgal SM, Degtiarev AA, Seryĭ SV, et al. The clinico-epidemiological efficacy of thymogen in acute respiratory viral infections in a military collective. Voen Med Zh. 1993.
  9. Khavinson VKh, Kozhemiakin AL, Volgarev AP, et al. The protective effect of peptides from the thymus and tracheal mucosa in an experimental respiratory influenzal infection. Zh Mikrobiol Epidemiol Immunobiol. 1993.
  10. Deplanque G, Madhusudan S, Jones PH, et al. Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma. Br J Cancer. 2004.

Related Peptides

Track Thymogen in Your Protocol

Log your Thymogen doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free